Max Healthcare Alpha Trade Pick: Max Healthcare enters a multi-year expansion phase

    Synopsis:

    Max Healthcare is executing a structured expansion strategy centred on brownfield capacity additions, selective acquisitions, improving ARPOB, and disciplined capital deployment, supported by steady operating metrics and recent regulatory developments.

    Stock Snapshot

    Particulars

    Details

    Exchange

    NSE / BSE

    NSE/BSE Code

    MAXHEALTH / 543220

    CMP (₹)

    1,078

    Target Price (₹)

    1,218

    Upside (%)

    12%

    52-Week High / Low (₹)

    ₹1,314 / 940

    Market Capitalisation

    ₹1,055.46 bn

    Investment Rationale

    Max Healthcare is in an ongoing expansion cycle with defined capacity additions supported by sustained improvement in operating performance, capital deployment aligned with reported ROCE metrics and balance-sheet discipline. The company’s strategy prioritises brownfield expansions, selective inorganic growth and calibrated greenfield development, enabling capacity addition without diluting return metrics.

    Cumulative project capex of approximately ₹6,487 crore has been committed through FY29, significantly expanding the network’s potential capacity over the medium term. Despite the scale of expansion, return ratios remain strong, with network-level ROCE exceeding 28% and existing hospitals delivering nearly 38% ROCE. Net debt continues to be maintained below 1x EBITDA, providing flexibility for ongoing capital deployment.

    Shareholding %

    Particulars

    Q2FY26

    Q1FY26

    Q4FY25

    Promoter

    23.74

    23.74

    23.74

    FII

    51.80

    54.76

    54.74

    DII

    20.03

    17.41

    17.49

    Others

    4.43

    4.09

    3.94

    Promoter Pledge – 0.44%

    Brownfield Expansion and Inorganic Growth

    Brownfield projects and strategic acquisitions are expected to be the primary earnings drivers over FY26–FY28. The integration of Jaypee Healthcare (Noida) and Alexis Hospital (Nagpur) has accelerated scale while complementing high-margin brownfield expansions at Mohali, Nanavati-Max and Saket.

    Management highlights that brownfield additions benefit from shared infrastructure and overhead absorption, limiting incremental EBITDA drag and enabling faster margin normalisation. Upcoming developments at Vikrant, Vaishali and Dehradun further strengthen the core northern cluster. This blend of inorganic growth and operating leverage is expected to translate into incremental contribution from FY27 onwards.

    Greenfield and Asset-Light Expansion

    Alongside brownfield growth, Max Healthcare is executing a structured greenfield and asset-light expansion strategy. New hospitals at Gurugram Sector-56, Patparganj (Nirogi), Thane, Zirakpur, Pitampura and a new site in Lucknow expand the company’s geographic footprint beyond Delhi NCR and Mumbai.

    These projects diversify volume pools and are critical to sustaining growth as mature hospitals operate at occupancy levels close to 80%. Different project structures allow the company to maintain capital efficiency while expanding capacity.

    Volume Growth and ARPOB Improvement

    Existing hospitals continue to report strong throughput growth. Occupied bed days increased by 22% year-on-year in H1 FY26. Like-for-like ARPOB for hospitals operational prior to Q4 FY24 grew by approximately 6.8% year-on-year.

    ARPOB growth is driven by a higher contribution from oncology, transplants and complex surgical procedures, along with an improving payer mix. International patients contribute disproportionately to ARPOB and average length of stay, reflecting higher ARPOB contribution from select patient segments.

    Hospitals at Dwarka, Noida, Lucknow and Nagpur continue to scale, with visible headroom for improvement in occupancy, ARPOB and margins as they converge toward network averages. These units also strengthen feeder flows into metro quaternary centres.

    CGHS Tariff Revision – Regulatory Tailwind

    The revision in Central Government Health Scheme (CGHS) tariffs effective October 2025 is expected to provide an annual revenue uplift of approximately ₹200 crore. Creating a margin impact as outlined by management commentary from FY27. Linked government schemes such as ECHS provide additional revenue visibility.

    High-Margin Adjacencies and Digital Scale

    Adjacency businesses such as Max Lab and Max@Home continue to scale at a 15–30% CAGR with minimal capital intensity, enhancing ecosystem stickiness and return metrics.

    Digital channels now contribute nearly 30% of network revenues, supporting patient acquisition, improving utilisation and lowering customer acquisition costs. Digital scale continues to strengthen operating leverage across the hospital network.

    Q2 FY26 – Management Call Highlights

    Margin Profile and Operating Efficiency

    Metric

    Q2 FY26

    Network Operating EBITDA Margin

    26.9%

    Existing Hospitals EBITDA Margin

    27.5%

    H1 FY26 Network EBITDA Margin

    25.9%

    H1 FY26 Existing Hospitals Margin

    26.5%

    Dwarka Hospital EBITDA Margin

    15% at 81% occupancy

    Max Lab EBITDA Margin

    16%

    Physiotherapy Business EBITDA Margin

    20%

    • Strong Network Margins: Network operating EBITDA margin stood at 26.9% for Q2 FY26, with existing units improving to 27.5% (up 90 bps YoY and 200 bps sequentially).
    • H1 Performance: For H1 FY26, network operating EBITDA margin was 25.9%, with existing units achieving 26.5%. Unit-Level Economics: The Dwarka hospital reported robust profitability with an EBITDA margin of ~15% at 81% occupancy.
    • Ancillary Business Margins: Max Lab reported an EBITDA margin of ~16%, while the physiotherapy business delivered margins of ~20%.
    • Expansion Efficiency: Management expects brownfield expansions to be margin-accretive quickly, avoiding the typical EBITDA drag associated with new greenfield facilities.

    Management reiterated that brownfield expansions are expected to turn margin-accretive quickly, avoiding the typical EBITDA drag associated with greenfield hospitals.

    Financials

    Particulars

    FY26E

    FY27E

    FY28E

    Revenue (mn)

    1,02,658

    1,27,478

    1,49,816

    EBITDA (mn)

    27,493

    34,686

    42,586

    PAT (mn)

    16,785

    21,689

    27,472

    EPS (mn)

    17.27

    22.31

    28.26

    Growth (%)

       

    Revenue

    46.1

    24.2

    17.5

    EBITDA

    48.7

    26.2

    22.8

    PAT

    56.0

    29.2

    26.7

    Margins (%)

       

    EBITDA

    26.8

    27.2

    28.4

    PAT

    16.4

    17.0

    18.3

    Valuation (x)

       

    P/E

    63.1

    48.8

    38.5

    P/B

    9.8

    8.3

    7.0

    EV/EBITDA

    44.4

    35.1

    28.1

    DEBT/EQUITY

    0.3

    0.2

    0.1

    ROCE (%)

    16.8

    19.2

    21.0

    ROE (%)

    15.5

    17.1

    18.3

    Financials & Ratio Analysis

    Income Statement

      

    (Rs in mn)

    Particulars

    FY26E

    FY27E

    FY28E

    Revenue from Operation

    1,02,658.2

    1,27,477.5

    1,49,816.2

    COGS

    21,434.4

    25,495.5

    29,963.2

    % of Sales

    20.9

    20.0

    20.0

    Gross Profit

    81,223.8

    1,01,982.0

    1,19,852.9

    Gross margin (%)

    79.1

    80.0

    80.0

    Employee Benefit Exp

    17,036.8

    21,338.0

    24,499.7

    Other expenses

    36,694.1

    45,958.1

    52,767.7

    EBITDA

    27,493.0

    34,686.0

    42,585.5

    EBITDA Margins (%)

    26.8

    27.2

    28.4

    Other Income

    2,053.2

    2,549.6

    2,996.3

    Depreciation

    4,960.9

    5,622.6

    6,046.8

    EBIT

    24,585.2

    31,612.9

    39,535.0

    EBIT Margins (%)

    23.9

    24.8

    26.4

    Finance Cost

    1,902.2

    1,902.2

    1,902.2

    Profit before tax

    22,683.0

    29,710.7

    37,632.8

    Total Tax expenses

    5,897.6

    8,021.9

    10,160.9

    Tax rate (%)

    26.0

    27.0

    27.0

    Profit after tax

    16,785.4

    21,688.8

    27,472.0

    PAT Margins

    16.4

    17.0

    18.3

    Basic EPS

    17.3

    22.3

    28.3

    Balance Sheet

      

    (Rs in mn)

    Particulars

    FY26E

    FY27E

    FY28E

    ASSETS

       

    Fixed Assets

    44,089.8

    49,352.2

    53,548.4

    CWIP

    22,400.0

    18,900.0

    8,440.0

    Goodwill

    37,145.6

    41,579.1

    45,114.4

    Trade Receivable

    11,335.2

    14,075.7

    16,542.2

    Inventories

    1,551.3

    1,926.4

    2,263.9

    Financial Assets

    2,621.8

    2,621.8

    2,621.8

    Cash and cash equivalent

    3,190.0

    8,198.8

    28,879.6

    Other Assets

    43,930.0

    51,011.5

    56,133.3

    Total Assets

    1,66,263.8

    1,87,665.5

    2,13,543.6

    EQUITY

       

    Equity Share Capital

    9,721.4

    9,721.4

    9,721.4

    Other Equity

    98,522.8

    1,17,175.1

    1,40,801.0

    Total Equity

    1,08,244.2

    1,26,896.5

    1,50,522.4

    Long Term Borrowings

    30,399.6

    30,399.6

    30,399.6

    Short Term Borrowings

    7,644.9

    7,644.9

    7,644.9

    Trade Payables

    11,724.2

    14,473.6

    16,725.8

    Other Liabilities

    8,250.9

    8,250.9

    8,250.9

    Total Liabilities

    58,019.6

    60,769.0

    63,021.2

    Total Equity and Liabilities

    1,66,263.8

    1,87,665.5

    2,13,543.6

    Cash Flow Statement

      

    (Rs in mn)

    Particulars

    FY26E

    FY27E

    FY28E

    Cash Flow from operating activities (OA)

    PBT

    22,683.0

    29,710.7

    37,632.8

    Depreciation

    4,960.9

    5,622.6

    6,046.8

    Operating Profit before WC change

    29,546.2

    37,235.6

    45,581.8

    Changes in Assets and liability

    (418.8)

    (366.2)

    (551.9)

    Cash from Operations

    29,127.4

    36,869.4

    45,029.9

    Tax

    (5,897.6)

    (8,021.9)

    (10,160.9)

    Net Cash from OA

    23,229.8

    28,847.5

    34,869.1

    Cash Flow from investing activities (IA)

    Capex

    (22,400.0)

    (18,900.0)

    (8,440.0)

    Net Cash from IA

    0.0

    0.0

    0.0

    Cash Flow from financing activities (FA)

    Finance Cost

    (1,902.2)

    (1,902.2)

    (1,902.2)

    Dividend

    (2,350.0)

    (3,036.4)

    (3,846.1)

    Net Cash from FA

    (4,252.2)

    (4,938.7)

    (5,748.3)

    Net increase/(decrease) in Cash

    (3,422.4)

    5,008.8

    20,680.8

    Cash at the beginning of the year

    6,612.4

    3,190.0

    8,198.8

    Cash at the end of the year

    3,190.0

    8,198.8

    28,879.6

    Ratio Analysis

       

    Particulars

    FY26E

    FY27E

    FY28E

    Growth (%)

       

    Revenue

    46.1

    24.2

    17.5

    Gross Profit

    46.3

    25.6

    17.5

    EBITDA

    48.7

    26.2

    22.8

    EBIT

    53.3

    31.0

    26.7

    PAT

    56.0

    29.2

    26.7

    % Of Revenue

       

    Gross Profit

    79.1

    80.0

    80.0

    EBITDA

    26.8

    27.2

    28.4

    EBIT

    23.9

    24.8

    26.4

    PAT

    16.4

    17.0

    18.3

    Return Ratios (%)

       

    ROCE

    16.8

    19.2

    21.0

    ROE

    15.5

    17.1

    18.3

    Valuation (x)

       

    P/E

    63.1

    48.8

    38.5

    P/B

    9.8

    8.3

    7.0

    EV/EBITDA

    44.4

    35.1

    28.1

    EV/ Sales

    11.9

    9.5

    8.0

    DEBT/EQUITY

    0.3

    0.2

    0.1

    Pricing Environment and Payer Mix

    Parameter

    Update

    CGHS Tariff Impact

    ₹200+ crore benefit

    EBITDA Flow-through

    85–90% by FY27

    ARPOB Growth (Existing Units)

    7% YoY

    International Patient ARPOB

    30% higher than average

    • CGHS Price Revision: A revision in Central Government Health Scheme (CGHS) prices effective October 13th is expected to generate a benefit of over INR 200 crores once fully implemented.
    • High Flow-Through: Management projects a significant flow-through of the CGHS pricing benefit, with 85-90% expected to hit EBITDA by FY27.
    • ARPOB Growth: Average Revenue Per Occupied Bed (ARPOB) for existing units (excluding new acquisitions) grew by 7% YoY.
    • Premium Payer Mix: International patients continue to drive premium pricing, generating approximately 30% higher ARPOB compared to the average patient.
    • Insurance Relations: Temporary issues with insurers regarding cashless facilities have been resolved, with future price revisions successfully agreed upon.

    Temporary cashless-facility issues with insurers have been resolved, with future price revisions successfully negotiated.

    Capital Expenditure and Capacity Pipeline

    Item

    Details

    H1 FY26 Capex

    ₹891 crore

    Land & Brownfield Additions

    ₹131 crore

    H2 FY26 Capex Guidance

    ₹1,100 crore

    • Capex Guidance: The company has earmarked approximately INR 1,100 crores for capital expenditure in H2 FY26.
    • Recent Deployments: In H1 FY26, INR 891 crores was deployed for expansion projects and upgrades, plus INR 131 crores for land purchases and brownfield expansion at Max Vaishali.
    • Upcoming Capacity: Significant capacity is coming online immediately:
      • A 268-bed tower at Nanavati Max (commissioning week of Nov 17).
      • A 400-bed tower at Max Smart (commissioning within 30 days).
      • A 160-bed tower at Mohali (already commissioned).
    • Project Pipeline: Strategic projects are progressing, with master plans finalized for the Thane project and building plan approvals awaited for the Pitampura, Delhi project.

    Upcoming Capacity Additions

    Project

    Status

    Nanavati-Max

    268-bed tower commissioning mid-November

    Max Smart Hospital

    400-bed tower commissioning shortly

    Mohali

    160-bed tower commissioned

    Thane

    Master plan finalised

    Pitampura (Delhi)

    Building approvals awaited

    Product Portfolio and Digital Traction

    • Oncology Expansion: New radiation oncology programs are scaling up, with a launch at the new Mohali tower and an upcoming launch in Lucknow within two weeks.
    • Digital Revenue Growth: Digital channels (online marketing, web appointments) are now a major revenue driver, generating INR 803 crores (30% of overall revenue), supported by a 53% YoY increase in website traffic.

    Corporate Actions and Updates

    Item

    Update

    Subsidiary Merger

    Crosslay Remedies merged with Jaypee Healthcare

    One-Time Benefit

    ₹149 crore

    Asset Divestment

    Chitta and Anoopshahr hospitals divested

    Dividend Paid (Q2 FY26)

    ₹146 crore

    • Merger Synergies: A merger between wholly-owned subsidiaries Crosslay Remedies and Jaypee Healthcare was approved, resulting in a one-time benefit of INR 149 crores.
    • Asset Monetization: The company completed the divestment of hospitals in Chitta and Anoopshahr in September 2025.
    • Shareholder Returns: Dividends of INR 146 crores were paid out during Q2 FY26.

    Competition and Talent Management

    • Competitive Positioning: Management dismissed concerns regarding competitor capacity additions in Noida and Lucknow, noting these were long-anticipated and less disruptive than their own Jaypee acquisition.
    • Talent Stability: Doctor attrition remains normal at 1-1.5%; the departure of some senior doctors in NCR had no business impact as they were immediately replaced.

    Valuation

    Max Healthcare’s expansion pipeline includes phased brownfield additions, new greenfield hospitals and asset-light facilities across major metros and emerging clusters. As newer hospitals ramp up and utilisation improves, the EBITDA base is expected to expand meaningfully by FY28. Applying a 28x EV/EBITDA multiple to FY28 earnings implies a target price of ₹1,218, representing an upside of 12% from current levels.

    Conclusion

    Max Healthcare’s disclosures indicate a measured expansion phase anchored in brownfield-led capacity addition and selective inorganic growth, aimed at preserving return metrics and operating efficiency. Mature hospitals continue to support margins, while newer units offer visibility on incremental utilisation gains. Capital allocation remains aligned with leverage thresholds, and contributions from digital channels and adjacency businesses add diversification. Execution of the expansion pipeline, occupancy ramp-up, and regulatory implementation remain the primary operational variables to monitor.

    Disclaimer :

    Investments in securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.


    The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.

    The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and/or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

    Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

    BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.



    Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited



    This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing. 

    For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

    Read More Blogs

    Publish Date: 16 Dec 2025

    Our Secure Trading Platforms

    Level up your stock market experience: Scan the QR to download the Bajaj Broking App for effortless investing and trading

    QR code to download Bajaj Broking App

    1 M+ Users

    4.8 App Rating

    4 Languages

    ₹7,300 Cr+ MTF Book

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |